Printer Friendly

EPO ruling opens doors for other isoflavones.

The European Patent Office (EPO) has rejected large parts of the Novogen patent claims, as originally granted in 2004, for the use of isoflavone phyto-oestrogen extracts. The patent, EP 0656786, was originally submitted to the EPO for approval in 1993. Following objections submitted by 10 European groups from Germany, France, Spain, Italy and the UK, and by Solbar (Israel), the EPO finally restricted claims wherein the isoflavone phytoestrogen extract comprises genistein and daidzein (aglycones) from soybeans and biochanin A or formononetin in red clover "in a ratio of about 1:2 to 2:1." Solgen natural soy isoflavone extracts, marketed and produced by Solbar Industries Ltd, are processed from the whole soybean in their natural form. Solgen glycoside phytoestrogens contain 55% genistin (minimum), approximately 40% daidzin and 5% glycitin. The approved part of the Novogen patent clearly states "Medicament" for the "treatment of premenstrual syndrome or symptoms associated with menopause." In accordance with the Council of Responsible Nutrition symposium (May 2009, Milan) on the Efficacy and Safety of Isoflavones for Postmenopausal Women, Solbar's Solgen soy isoflavones are designed to alleviate the symptoms experienced by postmenopausal women as used in non-medical nutraceutical products. Until an official statement of approval is received from the European Food Safety Authority (EFSA), a "treatment" claim is not possible. Solbar is a leading manufacturer of isolated soy proteins, textured soy and natural phytochemical extracts from the soybean. Solbar is dedicated to developing products that provide significant contributions to human nutrition and wellness (


COPYRIGHT 2009 Via Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:news; European Patent Office
Publication:Nutraceutical Business & Technology
Article Type:Brief article
Geographic Code:4EUUK
Date:Sep 1, 2009
Previous Article:Glanbia opens cutting-edge fortification facility.
Next Article:BioFlu: a natural defence against swine flu?

Related Articles
AstraZeneca loses patent - and nearly pounds 2bn of value; IN ASSOCIATION WITH Rensburg Sheppards SIPP PENSION PROVISION.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters